Hemispherx BioPharma, Inc  

(Public, NYSEMKT:HEB)   Watch this stock  
Find more results for NYSEAMEX:HEB
+0.123 (21.30%)
Real-time:   3:38PM EDT
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.58 - 0.75
52 week 0.39 - 2.64
Open 0.60
Vol / Avg. 765,863.00/193,445.00
Mkt cap 18.56M
P/E     -
Div/yield     -
EPS -0.35
Shares 26.19M
Beta -0.28
Inst. own 14%
May 15, 2017
Q1 2017 Hemispherx Biopharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 7, 2017
Q4 2016 Hemispherx Biopharma Inc Earnings Call - Webcast
Mar 31, 2017
Q4 2016 Hemispherx Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -7331.25% -8154.35%
Operating margin -25181.25% -13236.96%
EBITD margin - -13588.04%
Return on average assets -23.26% -36.00%
Return on average equity -29.29% -41.83%
Employees 32 -
CDP Score - -


One Penn Center 1617 Jfk Blvd, Suite #500
United States - Map
+1-215-9880080 (Phone)
+1-215-9881739 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Officers and directors

William M. Mitchell M.D., Ph.D. Chairman of the Board
Age: 81
Bio & Compensation  - Reuters
Thomas K. Equels Esq. Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
Age: 64
Bio & Compensation  - Reuters
Adam Pascale CPA Chief Financial Officer
Age: 68
Bio & Compensation  - Reuters
Wayne Steven Springate Senior Vice President - Operations
Age: 45
Bio & Compensation  - Reuters
David R. Strayer M.D. Chief Scientific & Medical Officer
Age: 70
Bio & Compensation  - Reuters
Peter W. Rodino III, Esq. Executive Director - Governmental Relations, General Counsel
Age: 65
Bio & Compensation  - Reuters
Stewart L. Appelrouth Director
Bio & Compensation  - Reuters